trans-5-Methyl-2-hexenyl-methylaether | 50426-59-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: trans-5-Methyl-2-hexenyl-methylaether
• 英文别名: 1-methoxy-5-methyl-hex-2t-ene；(E)-1-methoxy-5-methylhex-2-ene
• CAS: 50426-59-0
• 化学式: C₈H₁₆O
• 分子量: 128.214
• InChiKey: PTAMZBNPZZADFI-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  甲醇 、 1,3-丁二烯 、 异丁酸 生成 trans-5-Methyl-2-hexenyl-methylaether 、 3-methoxy-5-methyl-hex-1-ene 、 2,11-Dimethyldodecadien-(4,8), trans, trans 、 (E)-2,7-dimethyl-4-octene
  参考文献：
  名称：

  Bruno,F.; Dubois,J.-E., Bulletin de la Societe Chimique de France, 1973, p. 2270 - 2275

  摘要：

  DOI：

文献信息

• METHOD FOR MANUFACTURING KETONE
  申请人：Kaneda Kiyotomi

  公开号：US20120197036A1

  公开（公告）日：2012-08-02

  A method for manufacturing a ketone, includes oxidizing an internal olefin or a cyclic olefin having a functional group containing a hetero atom and one carbon-carbon double bond or more at a position other than terminals of a molecule thereof in an amide-based solvent in the presence of water, a palladium catalyst, and molecular oxygen, without oxidizing the functional group, thereby bonding an oxo group to at least one of the carbon atoms constituting the carbon-carbon double bond. The amide-based solvent is represented by formula (1): wherein R 1 represents an alkyl group having 1 to 4 carbon atoms; R 2 and R 3 each independently represent an alkyl group having 1 to 4 carbon atoms or an aryl group; and when R 1 and R 2 are alkyl groups, R 1 and R 2 may be bonded to each other to form a ring structure.

  一种制备酮的方法，包括在酰胺基溶剂中，在水、钯催化剂和分子氧的存在下氧化具有异原子和一个或多个碳碳双键的内部烯烃或环烯烃，其功能团位于分子的端部以外的位置，而不氧化功能团，从而将氧代基键合到构成碳碳双键的至少一个碳原子上。酰胺基溶剂由式（1）表示：其中R1代表具有1至4个碳原子的烷基基团；R2和R3各自独立地代表具有1至4个碳原子的烷基基团或芳基；当R1和R2为烷基基团时，R1和R2可以结合在一起形成环结构。
• METHOD FOR PRODUCING KETONE
  申请人：JX Nippon Oil & Energy Corporation

  公开号：EP2487149A1

  公开（公告）日：2012-08-15

  A method for manufacturing a ketone, comprising: oxidizing an internal olefin or a cyclic olefin having a functional group containing a hetero atom and one carbon-carbon double bond or more at a position other than terminals of a molecule thereof in an amide-based solvent in the presence of water, a palladium catalyst, and molecular oxygen, without oxidizing the functional group, thereby bonding an oxo group to at least one of the carbon atoms constituting the carbon-carbon double bond, the amide-based solvent being represented by the following formula (1) : (in the formula (1), R1 represents an alkyl group having 1 to 4 carbon atoms; R2 and R3 each independently represent an alkyl group having 1 to 4 carbon atoms or an aryl group; and when R1 and R2 are alkyl groups, R1 and R2 may be bonded to each other to form a ring structure).

  一种制造酮的方法，包括：在水、钯催化剂和分子氧的存在下，在酰胺基溶剂中氧化内烯烃或环状烯烃，该内烯烃或环状烯烃的官能团在其分子末端以外的位置上含有一个杂原子和一个或多个碳碳双键，但不氧化该官能团，从而将氧官能团键合到构成碳碳双键的至少一个碳原子上，酰胺基溶剂由下式(1)表示： 式（1）中，R1 代表具有 1 至 4 个碳原子的烷基；R2 和 R3 各自独立地代表具有 1 至 4 个碳原子的烷基或芳基；当 R1 和 R2 为烷基时，R1 和 R2 可相互键合以形成环状结构）。
• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：Qiu Yao-Ling

  公开号：US20100233122A1

  公开（公告）日：2010-09-16

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• HEPATITIS C VIRUS INHIBITORS
  申请人：Or Yat Sun

  公开号：US20100260715A1

  公开（公告）日：2010-10-14

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US8101643B2
  申请人：——

  公开号：US8101643B2

  公开（公告）日：2012-01-24